---
figid: PMC3661399__1471-2407-13-235-7
figlink: /pmc/articles/PMC3661399/figure/F7/
number: F7
caption: Overview of selected AMPK and IGF-IR signalling pathways relevant to this
  study in normal (A) and hyperglycaemic (B) conditions. In normal conditions, metformin
  activates AMPKThr172 through the LKB1 signalling pathway. Activated AMPK inhibits
  cell growth by repressing mTOR activity through activation of TSC2 and phosphorylation
  of inhibitory serine residues on IRS-1. In addition, as demonstrated in the present
  study, metformin suppresses IGF-IR activation and reduces IRS-1 levels, which disable
  further signalling through the PI3K/Akt pathway. During hyperglycaemia, signalling
  through the IGF-IR pathway appears more robust, leading to phosphorylation of Akt
  and AMPKSer485. This inhibitory Ser485 site can inhibit activation of AMPKThr172,
  possibly contributing to the impaired growth inhibitory effect by metformin at high
  glucose conditions.
pmcid: PMC3661399
papertitle: Metformin-mediated growth inhibition involves suppression of the IGF-I
  receptor signalling pathway in human pancreatic cancer cells.
reftext: Emelie Karnevi, et al. BMC Cancer. 2013;13:235-235.
pmc_ranked_result_index: '2060'
pathway_score: 0.8895287
filename: 1471-2407-13-235-7.jpg
figtitle: Selected AMPK and IGF-IR signalling pathways relevant to this study in normal
  (A) and hyperglycaemic (B) conditions
year: '2013'
organisms:
- Nicotiana tabacum
- Gallus gallus
- Homo sapiens
- Bos taurus
ndex: 15836b22-df16-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3661399__1471-2407-13-235-7.html
  '@type': Dataset
  description: Overview of selected AMPK and IGF-IR signalling pathways relevant to
    this study in normal (A) and hyperglycaemic (B) conditions. In normal conditions,
    metformin activates AMPKThr172 through the LKB1 signalling pathway. Activated
    AMPK inhibits cell growth by repressing mTOR activity through activation of TSC2
    and phosphorylation of inhibitory serine residues on IRS-1. In addition, as demonstrated
    in the present study, metformin suppresses IGF-IR activation and reduces IRS-1
    levels, which disable further signalling through the PI3K/Akt pathway. During
    hyperglycaemia, signalling through the IGF-IR pathway appears more robust, leading
    to phosphorylation of Akt and AMPKSer485. This inhibitory Ser485 site can inhibit
    activation of AMPKThr172, possibly contributing to the impaired growth inhibitory
    effect by metformin at high glucose conditions.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - STK11
  - PRKAB1
  - AKT2
  - TSC2
  - PIK3R3
  - PRKAA2
  - IRS1
  - IGF1R
  - IGF1
  - PIK3CG
  - PRKAA1
  - PRKAG2
  - PRKAG1
  - PRKAB2
  - AKT3
  - PIK3CA
  - PIK3R6
  - PRKAG3
  - PIK3CD
  - PIK3R4
  - MTOR
  - PIK3R5
  - PIK3CB
  - AKT1
  - Glucose
  - Metformin
genes:
- word: LKB1
  symbol: LKB1
  source: hgnc_alias_symbol
  hgnc_symbol: STK11
  entrez: '6794'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAB1
  entrez: '5564'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: TSC2
  symbol: TSC2
  source: hgnc_symbol
  hgnc_symbol: TSC2
  entrez: '7249'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAA2
  entrez: '5563'
- word: IRS-1
  symbol: IRS1
  source: hgnc_symbol
  hgnc_symbol: IRS1
  entrez: '3667'
- word: IGF-IR
  symbol: IGFIR
  source: hgnc_alias_symbol
  hgnc_symbol: IGF1R
  entrez: '3480'
- word: IGF-I
  symbol: IGF-I
  source: hgnc_alias_symbol
  hgnc_symbol: IGF1
  entrez: '3479'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAA1
  entrez: '5562'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAG2
  entrez: '51422'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAG1
  entrez: '5571'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAB2
  entrez: '5565'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAG3
  entrez: '53632'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: mTor
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
chemicals:
- word: Glucose
  source: MESH
  identifier: D005947
- word: Metformin
  source: MESH
  identifier: D008687
diseases: []
figid_alias: PMC3661399__F7
redirect_from: /figures/PMC3661399__F7
figtype: Figure
---
